The long-term objective of this SCOR is to further our understanding of the pathogenesis of the idiopathic interstitial pneumonias (UP). A clear understanding of the pathogenesis of these diseases is required to develop new treatment strategies. The central hypothesis for this SCOR proposal is: Local alterations in the elaboration of effector molecules or in the expression of receptors by inflammatory, epithelial, and mesenchymal cells create an alveolar microenvironment that favors the fibroproliferative response rather than normal repair. Such dysregulation in autocrine and/or paracrine regulatory loops determine susceptibility to and expression of fibrotic lung disease. In each project of this SCOR, this central hypothesis will be extended to define the role of a specific set of mediators and/or receptors in pathobiological processes relevant to fibrogenesis. These mediators include cytokines, chemokines, elcosanoids and proteases. Studies will utilize animal models of fibrosis and/or patients with HP to examine abnormalities in cells and tissues and the role of each mediator in the pathobiology of fibrosis. An important feature is the mechanistic insights these studies provide to the use of standard (prednisone, azathioprine + prednisone) and novel (5-lipoxygenase inhibitor, zileuton) therapeutic agents under investigation in our ongoing clinical project. This SCOR will take a multi-disciplinary approach to testing these hypotheses. The expertise of investigators trained in Internal Medicine, Pathology, Cell and Molecular Biology, Biochemistry, and Biostatistics will be utilized. The strength of this proposal are the investigators long-standing interests in fibrotic lung disease, a proven commitment to collaborative research by both clinicians and basic scientists, access to a large population of IIP patients, and extraordinary institutional resources of biomedical Research. This SCOR capitalizes on a bench to bedside continuum of research that is crucial to translate advances in basic research to the clinical arena.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
2P50HL056402-06
Application #
6346721
Study Section
Special Emphasis Panel (ZHL1-CSR-J (M1))
Program Officer
Reynolds, Herbert Y
Project Start
2001-12-26
Project End
2006-11-30
Budget Start
2001-12-26
Budget End
2002-11-30
Support Year
6
Fiscal Year
2002
Total Cost
$1,987,709
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Schmidt, S L; Nambiar, A M; Tayob, N et al. (2011) Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema. Eur Respir J 38:176-83
Trujillo, Glenda; Meneghin, Alessia; Flaherty, Kevin R et al. (2010) TLR9 differentiates rapidly from slowly progressing forms of idiopathic pulmonary fibrosis. Sci Transl Med 2:57ra82
Fell, Charlene D; Martinez, Fernando J; Liu, Lyrica X et al. (2010) Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 181:832-7
Huang, Steven K; White, Eric S; Wettlaufer, Scott H et al. (2009) Prostaglandin E(2) induces fibroblast apoptosis by modulating multiple survival pathways. FASEB J 23:4317-26
Fell, Charlene D; Liu, Lyrica Xiaohong; Motika, Caroline et al. (2009) The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 179:402-7
White, Kimberly E; Ding, Qiang; Moore, Bethany B et al. (2008) Prostaglandin E2 mediates IL-1beta-related fibroblast mitogenic effects in acute lung injury through differential utilization of prostanoid receptors. J Immunol 180:637-46
Huang, Steven K; Peters-Golden, Marc (2008) Eicosanoid lipid mediators in fibrotic lung diseases: ready for prime time? Chest 133:1442-50
Han, M K; Murray, S; Fell, C D et al. (2008) Sex differences in physiological progression of idiopathic pulmonary fibrosis. Eur Respir J 31:1183-8
Muro, Andres F; Moretti, Federico A; Moore, Bethany B et al. (2008) An essential role for fibronectin extra type III domain A in pulmonary fibrosis. Am J Respir Crit Care Med 177:638-45
Huang, Steven K; Wettlaufer, Scott H; Hogaboam, Cory M et al. (2008) Variable prostaglandin E2 resistance in fibroblasts from patients with usual interstitial pneumonia. Am J Respir Crit Care Med 177:66-74

Showing the most recent 10 out of 96 publications